SpringWorks Stock Analysis

SWTX
 Stock
  

USD 24.25  0.84  3.35%   

The small slide in market price for the last few months created some momentum for investors as it was traded today as low as 23.79 and as high as 25.94 per share. The company executives did not add much value to SpringWorks Therapeutics investors in November. However, diversifying your holdings with SpringWorks Therapeutics or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.54. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the SpringWorks Therapeutics partners.
Additionally, take a look at World Market Map.
  
The SpringWorks Therapeutics stock analysis report makes it easy to digest most publicly released information about SpringWorks Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. SpringWorks Stock analysis module also helps to analyze the SpringWorks Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

SpringWorks Stock Analysis Notes

About 92.0% of the company shares are owned by institutional investors. The book value of SpringWorks Therapeutics was at this time reported as 9.86. The company recorded a loss per share of 4.23. SpringWorks Therapeutics had not issued any dividends in recent years. SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Springworks Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people. To find out more about SpringWorks Therapeutics contact Saqib JD at 203 883 9490 or learn more at https://www.springworkstx.com.

SpringWorks Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. SpringWorks Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding SpringWorks Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
SpringWorks Therapeutics generated a negative expected return over the last 90 days
SpringWorks Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (173.91 M) with profit before overhead, payroll, taxes, and interest of 35 M.
SpringWorks Therapeutics currently holds about 334.54 M in cash with (127.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.81.
SpringWorks Therapeutics has a frail financial position based on the latest SEC disclosures
Over 92.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: PRECISION BIOSCIENCES INC Managements Discussion and Analysis of Financial Condition and Results of Operations. - Marketscreener.com

SpringWorks Therapeutics Upcoming and Recent Events

Earnings reports are used by SpringWorks Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to SpringWorks Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

SpringWorks Largest EPS Surprises

Earnings surprises can significantly impact SpringWorks Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-04
2021-09-30-0.76-0.84-0.0810 
2021-05-05
2021-03-31-0.51-0.62-0.1121 
2020-08-12
2020-06-30-0.36-0.47-0.1130 
View All Earnings Estimates

SpringWorks Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as SpringWorks Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading SpringWorks Therapeutics backward and forwards among themselves. SpringWorks Therapeutics' institutional investor refers to the entity that pools money to purchase SpringWorks Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.5 K128 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares80150 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares86355 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares85570 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares81560 K
Xtx Topco LtdCommon Shares7.1 K204 K
Xtx Topco LtdCommon Shares4.7 K294 K
Note, although SpringWorks Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

SpringWorks Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.57 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate SpringWorks Therapeutics's market, we take the total number of its shares issued and multiply it by SpringWorks Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

SpringWorks Profitablity

SpringWorks Therapeutics' profitability indicators refer to fundamental financial ratios that showcase SpringWorks Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, SpringWorks Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, SpringWorks Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of SpringWorks Therapeutics' profitability requires more research than a typical breakdown of SpringWorks Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(9.48) (10.23) 
Return on Average Assets(33.81) (36.48) 
Return on Average Equity(35.51) (38.32) 
Return on Invested Capital 0.26  0.28 
Return on Sales 0.14  0.15 

Management Efficiency

The entity has return on total asset (ROA) of (0.2741) % which means that it has lost $0.2741 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.4806) %, meaning that it created substantial loss on money invested by shareholders. SpringWorks Therapeutics management efficiency ratios could be used to measure how well springworks therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. SpringWorks Therapeutics Return on Invested Capital is fairly stable at the moment as compared to the past year. SpringWorks Therapeutics reported Return on Invested Capital of 0.26 in 2021. Return on Sales is likely to rise to 0.15 in 2022, whereas Return on Investment is likely to drop (10.23)  in 2022. SpringWorks Therapeutics Assets Non Current are fairly stable at the moment as compared to the past year. SpringWorks Therapeutics reported Assets Non Current of 24.68 Million in 2021. Total Assets Per Share is likely to rise to 11.26 in 2022, whereas Total Assets are likely to drop slightly above 357.9 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 6.37  9.09 
Enterprise Value over EBIT 6.30  6.80 
Enterprise Value over EBITDA 5.81  4.87 
Price to Book Value 1.66  1.52 
Tangible Assets Book Value per Share 9.51  14.04 
Enterprise Value55.5 M50.7 M
Tangible Asset Value55 M56.3 M

Technical Drivers

As of the 5th of December, SpringWorks Therapeutics has the coefficient of variation of (7,804), and Risk Adjusted Performance of (0.012225). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of SpringWorks Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for SpringWorks Therapeutics, which can be compared to its competition. Please validate SpringWorks Therapeutics maximum drawdown, as well as the relationship between the downside variance and skewness to decide if SpringWorks Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 24.25 per share. Given that SpringWorks Therapeutics has jensen alpha of (0.23), we advise you to double-check SpringWorks Therapeutics's current market performance to make sure the company can sustain itself at a future point.

SpringWorks Therapeutics Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. SpringWorks Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for SpringWorks Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

SpringWorks Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SpringWorks Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SpringWorks Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases SpringWorks Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Squinto Stephen P a day ago via Macroaxis 
Acquisition by Squinto Stephen P of 7464 shares of SpringWorks Therapeutics subject to Rule 16b-3
Ashar Bhavesh over a month ago via Macroaxis 
Acquisition by Ashar Bhavesh of 100000 shares of Springworks Therapeutics subject to Rule 16b-3
Cassidy James over a month ago via Macroaxis 
Springworks Therapeutics exotic insider transaction detected
Orbimed Advisors Llc over two months ago via Macroaxis 
Sale by Orbimed Advisors Llc of 30000 shares of Springworks Therapeutics
Lewishall Freda C over three months ago via Macroaxis 
Acquisition by Lewishall Freda C of 1106 shares of Springworks Therapeutics subject to Rule 16b-3
Orbimed Advisors Llc over three months ago via Macroaxis 
Sale by Orbimed Advisors Llc of 69568 shares of Springworks Therapeutics
Alban Carlos over three months ago via Macroaxis 
Acquisition by Alban Carlos of 30160 shares of Springworks Therapeutics subject to Rule 16b-3
Burgess Michael F over three months ago via Macroaxis 
Acquisition by Burgess Michael F of 12185 shares of Springworks Therapeutics subject to Rule 16b-3
Schwartz Jeffrey Lawrence over six months ago via Macroaxis 
Springworks Therapeutics exotic insider transaction detected
Schwartz Jeffrey Lawrence over six months ago via Macroaxis 
Acquisition by Schwartz Jeffrey Lawrence of 15318 shares of Springworks Therapeutics subject to Rule 16b-3
Lewishall Freda C over six months ago via Macroaxis 
Acquisition by Lewishall Freda C of 4818 shares of Springworks Therapeutics subject to Rule 16b-3
Pichl Daniel over six months ago via Macroaxis 
Payment of 631 shares by Pichl Daniel of Springworks Therapeutics subject to Rule 16b-3

SpringWorks Therapeutics Predictive Daily Indicators

SpringWorks Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of SpringWorks Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

SpringWorks Therapeutics Forecast Models

SpringWorks Therapeutics time-series forecasting models is one of many SpringWorks Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary SpringWorks Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About SpringWorks Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how SpringWorks Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling SpringWorks shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as SpringWorks Therapeutics. By using and applying SpringWorks Stock analysis, traders can create a robust methodology for identifying SpringWorks entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 0.40  0.35 

Current SpringWorks Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. SpringWorks analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. SpringWorks analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
114.75Strong Buy4Odds
SpringWorks Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most SpringWorks analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand SpringWorks stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of SpringWorks Therapeutics, talking to its executives and customers, or listening to SpringWorks conference calls.
SpringWorks Analyst Advice Details

SpringWorks Stock Analysis Indicators

SpringWorks Therapeutics stock analysis indicators help investors evaluate how SpringWorks Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading SpringWorks Therapeutics shares will generate the highest return on investment. By understating and applying SpringWorks Therapeutics stock analysis, traders can identify SpringWorks Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow147654000.00
Logo U R LimglogosUSSWTX.png
Common Stock Shares Outstanding43300063.00
Total Stockholder Equity422396000.00
Total Cashflows From Investing Activities83592000.00
Property Plant And Equipment Net4197000.00
Retained Earnings-292513000.00
Cash And Short Term Investments373501000.00
Cash103961000.00
CodeSWTX
Accounts Payable3429000.00
Net Debt-102670000.00
50 Day M A25.2121
Total Current Liabilities29969000.00
Currency CodeUSD
Other Operating Expenses173468000.00
Non Current Assets Total69584000.00
Non Currrent Assets Other3274000.00
Additionally, take a look at World Market Map. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for analysis

When running SpringWorks Therapeutics price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Is SpringWorks Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SpringWorks Therapeutics. If investors know SpringWorks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SpringWorks Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.6 B
Return On Assets
(0.27) 
Return On Equity
(0.48) 
The market value of SpringWorks Therapeutics is measured differently than its book value, which is the value of SpringWorks that is recorded on the company's balance sheet. Investors also form their own opinion of SpringWorks Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is SpringWorks Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SpringWorks Therapeutics' market value can be influenced by many factors that don't directly affect SpringWorks Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SpringWorks Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine SpringWorks Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SpringWorks Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.